Dysmen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dysmen

Understanding Dysmen

Dysmen is a pharmaceutical formulation specifically designed to address the symptoms associated with primary and secondary dysmenorrhea, commonly known as menstrual cramps. It belongs to the class of medications intended to provide symptomatic relief from the physical discomfort that often precedes or accompanies a menstrual period.

Therapeutic Purpose

The primary objective of Dysmen is to mitigate the pain and inflammatory processes that occur within the uterine environment during menstruation. By targeting the underlying mechanisms of pelvic discomfort, the medication helps in managing the severity of cramps, allowing for improved physical function during the menstrual cycle.

Mechanism of Action

Dysmen typically functions by inhibiting the synthesis of prostaglandins. Prostaglandins are hormone-like substances produced by the lining of the uterus that cause the uterine muscles to contract. Higher levels of these substances are often linked to more severe menstrual pain. By reducing their production, Dysmen assists in:

  • Reducing the intensity of uterine contractions.
  • Lowering the sensitivity of pain receptors in the pelvic region.
  • Alleviating associated symptoms such as lower back pain and general pelvic heaviness.

Common Applications

Dysmen is utilized by individuals experiencing various degrees of menstrual distress, ranging from mild discomfort to more acute pain that interferes with daily activities. While its main application is for menstrual-related pain, the properties of the active ingredients may also be effective for other localized inflammatory conditions as determined by a healthcare professional.

Regulatory References

  1. fenamates
  2. NSAID
  3. COX inhibitor

What side effects are possible with Dysmen ?

Possible Side Effects and Safety Information for Dysmen

Dysmen is a combination product whose safety profile is dictated by its active ingredients (an NSAID and an anticholinergic agent). All users should be aware of the potential for adverse effects and safety limitations as documented by regulatory bodies.

Adverse Reaction Scope

Common Adverse Reactions typically involve the Gastrointestinal and Nervous Systems, including: dizziness, sleepiness, headache, nausea, vomiting, diarrhea, stomach upset, and dry mouth. Blurred vision and nervousness are also commonly reported.

Serious Adverse Reactions documented in official labeling include:

  • Gastrointestinal (GI) Events: Severe bleeding, ulceration, or perforation of the stomach or intestines, which can be fatal and may occur without warning symptoms.
  • Cardiovascular (CV) Thrombotic Events: Increased risk of serious CV events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with the duration of use and in patients with pre-existing heart disease. The drug is contraindicated for pain management following Coronary Artery Bypass Graft (CABG) surgery.
  • Hypersensitivity: Severe, sometimes fatal, skin reactions (e.g., Stevens-Johnson syndrome) and anaphylactic reactions.

Safety Considerations and Restrictions

  • Pregnancy and Breastfeeding: The medication is highly contraindicated during pregnancy as it may cause fetal harm and problems with delivery. It is generally not recommended during breastfeeding due to the risk of toxicity to the infant.
  • Pre-existing Conditions: The drug is contraindicated in patients with severe kidney disease, active gastrointestinal ulcers or bleeding disorders, or a history of severe allergic reactions to NSAIDs.
  • Exposure-Related Patterns: The risk of serious cardiovascular and renal adverse events is associated with prolonged use.
  • Safety Monitoring: Due to the risk of dizziness and blurred vision, patients should exercise caution when operating machinery or driving until they know how the drug affects them. The concomitant use of alcohol may enhance drowsiness and increase the risk of GI problems.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Dysmen (Mefenamic Acid) defines the overdose profile primarily by its toxicological effects on the central nervous system, gastrointestinal tract, and renal system. Documented clinical manifestations of an overdose include neurological signs such as seizures (convulsions), headache, lethargy, somnolence, and tinnitus. Gastrointestinal symptoms like nausea, vomiting, and epigastric pain are also commonly reported.

Severe and potentially life-threatening outcomes documented in the label include generalized seizures, coma, and the risk of developing acute renal failure or significant Gastrointestinal bleeding.

Immediate medical attention must be sought for any suspected overdose due to the potential for these severe complications. Regulatory guidance confirms that no specific antidote is known for Mefenamic Acid. Therefore, treatment is defined as strictly symptomatic and supportive. This management requires close clinical monitoring, including the observation of vital signs and frequent assessment of renal function. Procedures such as the administration of activated charcoal may be considered for gastric decontamination if the ingestion was recent.

Special considerations noted in the official profile include an increased susceptibility to severe CNS effects in pediatric patients and an increased risk of acute renal failure in patients with pre-existing renal impairment.

Therapeutic Uses of Dysmen

Dysmen is a medication primarily relevant for easing the acute discomfort associated with the menstrual cycle. It is commonly used to help manage the symptoms of primary dysmenorrhea.

It is applied in addressing situations involving certain distressing symptoms and is relevant when supportive symptom management is appropriate. The medication is used for managing the symptom clusters of throbbing abdominal and pelvic pain, as well as associated manifestations like lower backache and pain radiating down the thighs. The drug is commonly used across conditions characterized by periods of heightened symptoms, which may interfere with routine functional stability.

“This type of supportive symptomatic relief may help patients cope more steadily with symptom fluctuations.”

The medication is relevant in contexts marked by increased discomfort or tension, and supports general well-being during symptomatic phases.


Quick Fact: Support for Cyclical Discomfort Dysmen is primarily used for managing symptoms associated with the temporary physiological imbalance of the menstrual cycle, rather than pain from chronic inflammation or injury.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dysmen (Mefenamic Acid)

Official regulatory guidelines strictly define the populations eligible to use Dysmen, an Nonsteroidal Anti-inflammatory Drug (NSAID), based primarily on age and pre-existing health conditions.

Contraindicated Populations

Dysmen is contraindicated and must not be used in individuals with a history of hypersensitivity to aspirin or other NSAIDs, or to any component of the formulation. Absolute exclusion applies to patients with active gastrointestinal ulceration, severe renal impairment, severe heart failure, and those undergoing Coronary Artery Bypass Graft (CABG) surgery. Use is also contraindicated during the last trimester of pregnancy (from 30 weeks gestation).

Eligibility and Restrictions

The medicine is approved for adults and adolescents aged 14 years and older. Safety and effectiveness have not been established for children younger than 14. Use requires caution in older adults due to increased risk of gastrointestinal and renal adverse events, and in patients with pre-existing hepatic impairment or mild-to-moderate renal impairment. Additionally, use is not recommended for women who are actively attempting to conceive, as it may impair female fertility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dysmen (Mefenamic Acid) has officially documented interaction patterns primarily concerning altered drug exposure and heightened bleeding risk, as detailed in regulatory prescribing information.

Formally Contraindicated Combinations

Co-administration with other Non-Aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors, is formally restricted due to the significant increase in risk for serious gastrointestinal adverse events. Use is also contraindicated for the management of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Pharmacokinetic Patterns

Interaction Type Interacting Substance Official Interaction Pattern
Pharmacodynamic Oral Anticoagulants Enhances anticoagulant effects, substantially increasing the risk of hemorrhage.
Pharmacodynamic SSRIs, Anti-platelet Agents Increases the documented risk of gastrointestinal bleeding.
Pharmacokinetic Lithium, Methotrexate Reduces the renal clearance, leading to elevated plasma levels.
Pharmacokinetic Antacids (Magnesium Hydroxide) Significantly increases the rate and extent of Mefenamic Acid absorption.

Restrictions and Special Considerations

A mandatory timing rule dictates that Dysmen should not be taken for 8 to 12 days following Mifepristone administration to avoid reducing the effect of Mifepristone. Consumption of alcohol is documented to increase the risk of gastrointestinal bleeding. Furthermore, the risk of acute renal failure due to interaction with RAAS inhibitors is explicitly noted to be increased in the elderly population.

Mechanism of Action

Dysmen modulates smooth muscle contractions by acting as an antagonist at the prostaglandin E2 receptor sub-type EP4. This interaction results in the inhibition of adenylyl cyclase activity. The corresponding decrease in intracellular cyclic adenosine monophosphate (cAMP) levels alters the cAMP cascade and downstream effector molecules within the smooth muscle cell.

This molecular activity contributes to a reduction in the influx of Ca^2+ ions, thereby modulating the duration of myometrial depolarization.

Dysmen also exhibits a dual effect on eicosanoid production, involving PGF2alpha production suppression alongside maintenance of cyclooxygenase-2 (COX-2) activity. Furthermore, the compound inhibits the NF-kappa B pathway, an intracellular signaling pathway integral to cellular response modulation.

Dosage and Administration Information

How to Use Dysmen: Administration Guidelines

Dysmen is a medication for oral administration using 250 mg capsules or 500 mg tablets. The usage protocol defines a clear structure for administration, frequency, and duration.

Dosing and Frequency

Treatment is initiated with an initial loading dose of 500 mg taken as a single administration. Following this first dose, the maintenance dose is 250 mg, administered every 6 hours as needed for symptomatic relief. The medicine is designed for use on an as-needed (PRN) basis, responding directly to the presence of symptoms.

Administration Conditions and Duration

An essential instruction for proper administration is that the medication must be taken with food or milk/water to help minimize potential gastrointestinal discomfort. For the treatment of primary dysmenorrhea, administration should commence at the onset of menstrual bleeding and associated pain. Guidelines indicate that the use of Dysmen is for a limited duration. For primary dysmenorrhea, treatment is typically restricted to 2 to 3 days, and for all acute pain indications, the total course must not exceed 7 days.

Population Rules

Use is generally restricted to patients 14 years of age and older. Guidelines emphasize the fundamental principle that the lowest effective dose for the shortest duration necessary should be used across all applicable populations.

These instructions define the operational framework for administering the drug.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dysmen (Mefenamic Acid)

Evidence for Use in Primary Dysmenorrhea (Menstrual Pain)

The research base for Mefenamic Acid related to primary dysmenorrhea involves numerous Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. This research has been conducted on women and adolescent girls with this condition, which is associated with fluctuating or episodic manifestations of physical discomfort during the menstrual cycle.

In these research contexts, Mefenamic Acid was studied in the setting of periods of heightened symptom activity. Research has explored comparisons of Mefenamic Acid against a non-active control (placebo) or against other agents studied for physical discomfort in this condition. Findings from these trials describe patterns observed in the study groups, such as data related to measured pain levels. Research does not determine whether an individual will respond similarly.

How Studies Tracked Pain and Symptom Relief

In trials, researchers carefully monitored several key factors related to outcomes related to physical discomfort. Studies primarily focused on patient-reported outcomes describing perceived discomfort. Research examined pain intensity using standardized rating scales and observed the frequency of participants needing to take additional medication, which was defined as rescue medication. Some studies also explored factors reflecting daily functioning or activity level.

Long-Term Studies and Follow-Up Observation Periods

The majority of the available evidence is relevant in trials assessing short-term or episodic symptom patterns. Research has shown that the follow-up durations were typically limited, covering only the symptomatic phase of one menstrual cycle or extending for up to three consecutive cycles.

Given that Mefenamic Acid is studied for episodic or acute changes in discomfort, the research priorities have focused on examining changes in symptoms during that short window. Consequently, long-term effects are not fully established. The existing evidence is largely structured around short-term observations and changes over an acute period.

What Is Still Uncertain About Dysmen Research

Comparative evidence is lacking for a comprehensive assessment of Mefenamic Acid against the entire current range of available Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for this indication. Additionally, data for certain groups remain insufficient, such as older women or those with significant underlying health conditions. The evidence quality varies across some studies, and research is ongoing to address these identified gaps.

Key Studies & References NHS Guidance on Period pain (Dysmenorrhoea) - Medications and Treatment

Frequently Asked Questions (FAQ)

Common questions about Dysmen (FAQ)


Q: How is Dysmen different from common over-the-counter pain relievers?

Official information classifies the active ingredient in Dysmen, Mefenamic Acid, as a Nonsteroidal Anti-inflammatory Drug (NSAID). A key difference noted in regulatory documentation is that Dysmen is generally designated as a prescription-only (Rx) medication, which differentiates its regulatory status from many over-the-counter pain relievers.


Q: Does Dysmen have a risk of becoming habit-forming?

Regulatory documents, such as the medication guide, do not list abuse or dependence as a recognized or common risk associated with this medication. The official product information focuses on risks related to the gastrointestinal and cardiovascular systems.


Q: Does Dysmen interact with birth control pills?

Official interaction information notes that combining the active ingredient in Dysmen with contraceptives containing drospirenone may increase blood potassium levels. This is a specific interaction described in prescribing documents.


Q: How quickly should I expect Dysmen to start working?

Pharmacokinetic data from regulatory documents provide insight into the drug's absorption. This information indicates that peak plasma concentrations of the active ingredient typically occur approximately one to four hours following administration.


Q: If I miss a dose of Dysmen, what should I do?

Patient information leaflets often advise a specific protocol if a dose is missed. Leaflet information indicates that a missed dose is generally taken when remembered, unless the time for the next scheduled dose is approaching. Guidance consistently states that a double dose is not recommended.


Q: Can men use Dysmen for pain relief, or is it only for women?

Regulatory dosing information specifies that Dysmen is approved for use by adults and adolescents aged 14 and older. While the primary indication often discussed is pain related to the menstrual cycle, the drug’s general therapeutic purpose is for relief of pain and inflammation.


Q: Is Dysmen safe for people with high blood pressure?

Official documents indicate the importance of healthcare provider awareness regarding a history of high blood pressure (hypertension). The product information states that monitoring is noted as a special consideration for these patients.


Q: Where can I find the official prescribing information for Dysmen?

Official prescribing information intended for health professionals is typically available through governmental resources. These resources include drug listings found on the FDA and DailyMed websites.


Q: What are the signs of a serious side effect from Dysmen?

Emergency symptoms described in patient guides include chest pain, difficulty breathing, slurred speech, weakness on one side of the body, swelling of the face or throat, and indications of internal bleeding, such as black, tarry stools.


Q: What is the difference between the brand name and generic version of Dysmen?

Regulatory documents list the active ingredient as Mefenamic Acid, which is the chemical component responsible for the drug’s effects. Official information references both the generic form (Mefenamic Acid capsules/tablets) and corresponding historical brand names.


Q: Are there specific instructions for what to do if an overdose of Dysmen is suspected?

Official patient information describes symptoms that may occur if an overdose is suspected. These signs include symptoms like extreme tiredness, severe stomach pain, coma, or signs of bleeding in the stool or vomit. The occurrence of these signs is noted in official documents as requiring urgent care.


Q: Why is a specific monitoring of blood work sometimes mentioned for Dysmen users?

Official information advises that a healthcare provider may order certain laboratory tests to monitor the body's response. This practice is often mentioned due to potential risks related to liver and kidney function, which the drug can affect.


Q: Can Dysmen interact with my daily vitamins or supplements?

Patient guides describe the importance of healthcare provider awareness regarding all medicines being taken, including vitamins and herbal supplements. Interactions between the active ingredient and other substances may occur, which is why a complete list of all products used is generally requested.


Q: Is there a maximum age limit for taking Dysmen?

Regulatory documents specify that the drug is approved for use in adults and adolescents aged 14 and older, but they do not specify a maximum age limit. However, official information does note that older adults may have an increased frequency of adverse reactions, such as gastrointestinal bleeding.


Q: Why do official documents mention specific liver warnings for Dysmen?

Regulatory documents indicate that caution is a consideration for patients with pre-existing liver dysfunction and list specific signs of potential liver injury. These signs can include the yellowing of the skin or eyes. These warnings are documented to reflect the official safety profile for these patient populations.


Q: How is the risk profile of Dysmen categorized by regulatory bodies?

Regulatory agencies have historically used classification systems to describe the risk profile of medications in certain scenarios. For example, the drug was previously categorized under Pregnancy Category C for use before the third trimester, reflecting a specific assessment of risk for the unborn fetus.


Q: Why is it important to know about all interactions before taking Dysmen?

Official documents explicitly state that interactions between medicines, vitamins, and supplements can occur. Knowing about all potential interactions is important because these combinations may change the way the medicine works or potentially lead to serious side effects.

How should Dysmen be stored and disposed of?

How to Store and Dispose of Dysmen (Mefenamic Acid)

Official regulatory guidelines define specific storage and disposal requirements for Dysmen (Mefenamic Acid).


Storage Conditions

Dysmen must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and excessive heat; therefore, do not refrigerate or freeze. Keep the medication in its original container and ensure the cap is tightly closed. Store the medication securely out of the sight and reach of children.


Disposal Instructions

Unused or expired Dysmen should preferably be disposed of through a dedicated drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance, seal it in a bag, and place it in the household trash. Do not flush Mefenamic Acid down the toilet or pour it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dysmen  found in:

A-Z Index: